BMS-707035 - HIV 抑制剂 - 生命科学试剂 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEBMS-707035Cat. No.: HY-13269CAS No.: 729607-74-3分式: CHFNOS分量: 410.42作靶点: HIV; HIV Integrase作通路: Anti-infection; Metabolic Enzyme/Protease储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 50 m

2、g/mL (121.83 mM; Need ultrasonic)H2O : 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (6.09 mM); Clear solution2. 请依序添加每种溶剂： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (6.09 mM); Clear solution1/2 Master of Small Molecules 您边的抑制剂师www.MedChemEBIOLOGICAL ACTIVITY物活性 BMS-707035是HIV-1整合酶（IN）抑制剂，

3、IC50为15 nM。REFERENCES1. Cotelle P.,3-Hydroxy-6,7-dihydropyrimido2,1-c1,4oxazin-4(9H)-ones as new HIV-1 integrase inhibitors WO2011046873 A1.,ExpertOpin Ther Pat. 2011 Nov;21(11):1799-804.2. Al-Mawsawi LQ, Al-Safi RI, Neamati N.,Anti-infectives: clinical progress of HIV-1 integrase inhibitors.,Expert

4、 Opin Emerg Drugs. 2008Jun;13(2):213-25.3. Dayam R, Al-Mawsawi LQ, Neamati N.,HIV-1 integrase inhibitors: an emerging clinical reality.,Drugs R D. 2007;8(3):155-68.4. Dicker IB, et al. Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, andthe binding of strand transfer inhibitors. J Biol Chem. 2007 Oct 26;282(43):31186-96.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792;